Analysis of cellular events using CellCard System in cell-based high-content multiplexed assays.
High-content screening technologies utilize assays that monitor and quantify multiple cellular events. These assays are typically performed on a single cell type with automated microscopy and image analysis. However, in order to better understand the selectivity of a compound across multiple cell lines, these types of assay must be run serially, which is time consuming. The CellCard System developed by Vitra Bioscience enables multiple cell types to be assayed within a single microtiter well, thereby enabling the simultaneous determination of cellular responses across ten cell types. This multiplexed approach could address the demand for assay capacity, increase the quality of the biologic data, reduce timelines, and improve cost-effectiveness in hit identification and lead evaluation. The authors have carried out an in-depth evaluation of this technology platform using ten cancer cell lines and a library of compounds that affect cellular growth through different mechanisms. Multiple assays were used to investigate the compound effects on membrane integrity, cell cycle progression and apoptosis. In this technology review, the authors discuss personal experience with assay validation, data analysis, results such as cell type-specific compound effects, and the potential application of the CellCard System in drug discovery.
Chen
Taosheng
T
Bristol-Myers Squibb Company, Lead Discovery & Profiling, 5 Research Parkway, Wallingford, CT 06492, USA. taosheng.chen@bms.com
Hansen
George
G
Beske
Oren
O
Yates
Kristin
K
Zhu
Yingjie
Y
Anthony
Monique
M
Agler
Michele
M
Banks
Martyn
M
D001681:Biological Assay / Q000379:methods*; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D002468:Cell Physiological Phenomena; D002470:Cell Survival; D006801:Humans
D053148:Caspase 3